Diabetes

DENVER — Women with type 2 diabetes prescribed any GLP-1 receptor agonist were less likely to develop any new-onset uterine fibroids over 5 years compared with those who used metformin or insulin, researchers reported.

SAN DIEGO — Semaglutide, a GLP-1 receptor agonist approved for treatment of obesity and type 2 diabetes, improved kidney metrics for adults with overweight and obesity without diabetes, according study data.

SAN DIEGO — Compared with placebo, finerenone was associated with reductions in albuminuria and decreased risk of new-onset albuminuria among adults with heart failure, according to data from the FINEARTS-HF trial.

Clinical and genetic risk factors can help identify individuals at risk for immune checkpoint inhibitor-induced diabetes, according to results of a cohort study.

DENVER — For women with polycystic ovary syndrome and overweight or obesity, neither oral contraceptive pills nor metformin altered the characteristic markers of metabolic syndrome, either alone or in combination, researchers reported.

Oral semaglutide demonstrated an approximately 14% reduction in major adverse CV events compared with standard care along in patients with diabetes, CVD and/or kidney disease, according to the top-line results of the phase 3 SOUL trial.

SGLT2 inhibitors and GLP-1 were more effective than dipeptidyl peptidase-4 inhibitors and sulfonylurea kidney complications .

Medtronic has issued an urgent medical device correction letter warning users of the MiniMed 600 and 700 series of insulin pumps of an increased risk for shorter-than-expected battery life, according to an FDA press release.

There have been many recent regulatory updates in the areas of blood pressure management, dyslipidemia and diabetes management, speakers reported.

An analysis of data from young adults with obesity revealed that exposure to higher levels of three types of per-and polyfluoroalkyl substances was associated with more sleep disturbances and shorter sleep duration.